Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332

• DOI: 10.1128/jvi.02013-21
• Publication Date: 2022-04-07T13:02:10Z
• Authors: Jian Li; Cheng Lin; Xuelan Zhou; Fanglin Zhong; Pei Zeng; Yang Yang; Yuting Zhang; Bo Yu; Xiaona Fan; Peter J. McCormick; Rui Fu; Yang Fu; Haihai Jiang; Jin Zhang
• Keywords: 0301 basic medicine; Lactams; Proline; SARS-CoV-2; Antiviral Agents; COVID-19 Drug Treatment; 3. Good health; 03 medical and health sciences; Severe acute respiratory syndrome-related coronavirus; Leucine; Vaccines and Antiviral Agents; Nitriles; Middle East Respiratory Syndrome Coronavirus; Humans; Protease Inhibitors; Peptide Hydrolases

The current pandemic of multiple variants has created an urgent need for effective inhibitors of SARS-CoV-2 to complement vaccine strategies. PF-07321332, developed by Pfizer, is the first orally administered coronavirus-specific main protease inhibitor approved by the FDA.